The mission of the UAB CFAR is to support UAB investigators in the conduct of multidisciplinary, cutting edge research in the prevention, pathogenesis, therapeutics, clinical care, and psychosocial manifestations of HIV and related disorders in the community, within the US and around the world. For 25 years, the Center has played a vital role in supporting research activities of its members that have led to paradigm-shifting discoveries, including: the discovery of HIV-1 quasi-species diversity, detection of HIV-1 RNA in plasma, viral dynamics in acute and chronic infection, first-in-human phase 1 clinical studies of 7 currently approved therapies, the zoonotic origins of HIV-1, and the direct use of outcomes research data to inform clinical practice. Strategic planning activities have focused our scientific agenda over the next 5 years to address: HIV pathogeneses, the natural history of HIV in the treatment era, drug discovery, and prevention. The objectives of the CFAR reflect this modern agenda and further our commitment to innovative, multidisciplinary AIDS research, including: 1. Provision of a central institutional focus for HIV/AIDS research activities that emphasize effective communication and collaboration among CFAR members and the wider HIV/AIDS research community. 2. Enhancement of productivity of ongoing research programs by encouraging interdisciplinary research and by providing critical shared resource facilities and administrative and fiscal management support to Center investigators. 3. Use of robust strategic planning methods to identify new research opportunities and priorities that align with existing CFAR programs and foster new research programs where none are in existence but where faculty interest and University capacity is evident. 4. To stimulate the entry of junior and established faculty into HIV/AIDS research programs through mentoring programs for young investigators and by a peer-reviewed Developmental Grants Program. 5. To stimulate faculty recruitment and program development in areas that reflect the ongoing evolution of HIV/AIDS research in Alabama, the United States, and around the world. The success of the UAB CFAR in stimulating HIV/AIDS research is reflected in the growth in extramural funding from $6.0 million in 1988 to over $86 million currently, in the recruitment of more than 24 HIV/AIDS investigators since 2009, high profile publications, and in the garnering of outstanding Institutional support. .

Public Health Relevance

The UAB CFAR will stimulate and facilitate HIV/AIDS research that has high local, national, and international impact and in so doing will promote the NIH priorities of innovation and effectiveness in AIDS treatment and prevention

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027767-28
Application #
9065697
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Namkung, Ann S
Project Start
1997-03-01
Project End
2019-05-31
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
28
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Peng, Binghao J; Carlson, Jonathan M; Liu, Michael K P et al. (2018) Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. J Virol 92:
Shi, Bi; Geng, Jianlin; Wang, Yin-Hu et al. (2018) Foxp1 Negatively Regulates T Follicular Helper Cell Differentiation and Germinal Center Responses by Controlling Cell Migration and CTLA-4. J Immunol 200:586-594
Moshiri, Niema; Mirarab, Siavash (2018) A Two-State Model of Tree Evolution and Its Applications to Alu Retrotransposition. Syst Biol 67:475-489
Crockett, Kaylee B; Rice, Whitney S; Turan, Bulent (2018) Associations Between Multiple Forms of Discrimination and Tobacco Use Among People Living With HIV: The Mediating Role of Avoidance Coping. J Acquir Immune Defic Syndr 78:9-15
Mai, Uyen; Mirarab, Siavash (2018) TreeShrink: fast and accurate detection of outlier long branches in collections of phylogenetic trees. BMC Genomics 19:272
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552
Ram, Daniel R; Manickam, Cordelia; Hueber, Brady et al. (2018) Tracking KLRC2 (NKG2C)+ memory-like NK cells in SIV+ and rhCMV+ rhesus macaques. PLoS Pathog 14:e1007104
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Rice, Whitney S; Logie, Carmen H; Napoles, Tessa M et al. (2018) Perceptions of intersectional stigma among diverse women living with HIV in the United States. Soc Sci Med 208:9-17
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72

Showing the most recent 10 out of 955 publications